BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, announces the launch of MAVERICK, an optical in-line analyzer that provides real-time monitoring and control of glucose, lactate, and total biomass in mammalian cell cultures, in addition to rich process fingerprint data to support large-scale efforts in predictive bioprocess modeling.

波士顿-（BUSINESS WIRE）-908 Devices Inc.（纳斯达克股票代码：MASS）是专门用于化学和生化分析的手持式和桌面设备的先驱，宣布推出MAVERICK，这是一款光学在线分析仪，可实时监测和控制哺乳动物细胞培养物中的葡萄糖，乳酸和总生物量，除了丰富的过程指纹数据，以支持预测生物过程建模的大规模努力。

MAVERICK is the first turn-key device to utilize Raman spectroscopy for bioprocess control, with no modeling and development required. With its in-line optical sampling probe, biopharmaceutical scientists and engineers can quickly develop their cell culture media and design feeding and control strategies..

MAVERICK是第一个利用拉曼光谱进行生物过程控制的关键设备，不需要建模和开发。凭借其在线光学采样探头，生物制药科学家和工程师可以快速开发细胞培养基，设计饲养和控制策略。。

MAVERICK offers all the advantages of Raman spectroscopy without the cost and complexities associated with conventional spectroscopic methods. MAVERICK’s purpose-built de novo models automatically process Raman spectra from a wide variety of culture media types and cell lines, delivering actionable process parameters or direct process control actions.

MAVERICK提供拉曼光谱的所有优点，而不需要与传统光谱方法相关的成本和复杂性。MAVERICK专门建立的de novo模型可自动处理来自各种培养基类型和细胞系的拉曼光谱，提供可操作的过程参数或直接的过程控制操作。

Open access to the raw process spectral data also enables Artificial Intelligence (AI) / Machine Learning (ML) experts to extend MAVERICK’s capabilities for more advanced predictive control of critical process parameters or quality attributes..

对原始过程频谱数据的开放访问还使人工智能（AI）/机器学习（ML）专家能够扩展MAVERICK的功能，以便对关键过程参数或质量属性进行更高级的预测控制。。

“Traditional Raman-based analyzers require a sharp learning curve for the user which is time-consuming for initial model building and continued model updates,” said Dr. Seongkyu Yoon, Professor in the Department of Chemical Engineering and the Ward Endowed Professor in Biomedical Sciences at the University of Massachusetts-Lowell.

“传统的基于拉曼的分析仪需要为用户提供清晰的学习曲线，这对于初始模型构建和持续的模型更新非常耗时，”化学工程系教授兼生物医学病房捐赠教授柳成庆博士说。马萨诸塞州洛厄尔大学的科学。

“With MAVERICK, all the hurdles of traditional Raman have been overcome. This device provides very good measurements independently of cell line, media, and scale, which is very beneficial.”.

“使用MAVERICK，传统拉曼的所有障碍都已被克服。该设备提供了非常好的测量，与细胞系，培养基和规模无关，这是非常有益的。”。

The MAVERICK hub can monitor up to six bioreactor modules simultaneously, with independent analog/digital control of feed systems for each. Remote real-time web access to bioreactor status and settings is also supported through the MAVERICK hub. Biopharmaceutical process development scientists and manufacturers will be able to enhance process understanding and implement dynamic control strategies quicker and easier, leading to faster time to market and more robust and efficient processes..

MAVERICK hub可同时监测多达六个生物反应器模块，每个模块都有独立的进料系统模拟/数字控制。MAVERICK hub还支持远程实时web访问生物反应器状态和设置。生物制药过程开发科学家和制造商将能够更快更轻松地增强过程理解并实施动态控制策略，从而加快上市时间，提高流程的稳健性和效率。。

“As the biopharmaceutical industry adopts Process Analytical Technologies to drive the advancement of Biopharma 4.0, scientists need an array of tools that enable them to monitor and control their process in real time,” said Christopher D. Brown, Chief Product Officer and co-founder of 908 Devices. “We are addressing this need with our full complement of devices.

首席产品官兼联合创始人克里斯托弗D.布朗说：“由于生物制药行业采用过程分析技术推动生物制药4.0的发展，科学家们需要一系列工具来使他们能够实时监控和控制其过程。”908个设备。“我们正在通过我们的全套设备来满足这一需求。

With MAVERICK, we are introducing a new platform that offers easy-to-integrate in-line analysis and control without the need for substantial expert configuration or set-up. In addition, as a spectroscopic-based device, MAVERICK is extensible to other analytes and parameters.”.

通过MAVERICK，我们推出了一个新平台，可以轻松集成在线分析和控制，而无需大量的专家配置或设置。此外，作为基于光谱的设备，MAVERICK可扩展到其他分析物和参数“。

908 Devices experts will share more details about MAVERICK during the following events, including at the BioProcess International (BPI) conference in Boston:

908设备专家将在以下活动中分享有关MAVERICK的更多详细信息，包括在波士顿举行的BioProcess International（BPI）会议上：

Webinar (virtual) – September 18 at 11am ET – Chris Brown, CPO and co-founder, and Graziella Piras, Senior Director of Strategic Marketing at 908 Devices, will co-present this webinar about advanced in-line monitoring for bioprocessing, which will introduce the MAVERICK solution to the marketplace.

网络研讨会（虚拟）-9月18日上午11点ET-CPO及其联合创始人Chris Brown和908设备战略营销高级总监Graziella Piras将共同举办关于生物处理先进在线监控的网络研讨会，将介绍MAVERICK解决方案进入市场。

Scientific presentation – September 19 at 9:30am ET – Chris Brown will host a session within the Cell Culture Track at BPI Boston titled, “In-line monitoring of bioprocess parameters for the 21st century,” which will outline advancements in Biopharma 4.0 and the current state of spectroscopy-based approaches..

科学报告-上午9:30的9月19日ET-克里斯·布朗将在BPI波士顿的细胞培养轨道上主持一个题为“21世纪生物过程参数的在线监测”的会议，该会议将概述生物制药4.0的进步和基于光谱的方法的现状。。

Breakfast seminar – September 19 at 10am ET – Nick Randall, Bioprocessing Product Manager at 908 Devices, will conduct a talk at BPI Boston about “out-of-the-box implementation of optical monitoring of critical process parameters,” which will showcase the benefits and use cases of MAVERICK.

早餐研讨会-上午9月19日上午10点-908设备的生物加工产品经理Nick Randall将在BPI Boston举行关于“关键工艺参数的光学监控的开箱即用实施”的演讲，这将展示MAVERICK的好处和用例。

You can also find 908 Devices at BPI Boston at booth #860.

您还可以在BPI Boston的＃860展位上找到908台设备。

Scientific presentation – September 28 at 9am CET – During the World Smart Bioprocessing Summit-Pharma 4.0 in Berlin, Steve Driscoll, Senior Scientist at 908 Devices, will speak about the strengths and limitations of in-line multivariate bioprocess analysis. You can also find 908 Devices at Table 6 during the summit..

科学介绍-9月28日上午9点-在柏林世界智能生物处理峰会Pharma 4.0期间，908设备的高级科学家Steve Driscoll将谈到在线多变量生物过程分析的优势和局限性。在峰会期间，您还可以在表6中找到908个设备。。

MAVERICK is part of 908 Devices’ suite of devices to help expedite bioprocessing development, including MAVEN – introduced earlier this year -- and REBEL. To learn more about 908 Devices, please visit: 908devices.com.

MAVERICK是908个设备套件的一部分，旨在帮助加快生物处理开发，包括今年早些时候推出的MAVEN和REBEL。要了解更多关于908设备的信息，请访问：908devices.com。

About 908 Devices

大约908个设备

908 Devices is revolutionizing chemical and biochemical analysis with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma/biopharma, forensics and adjacent markets.

The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic sampling and separations, software automation, and machine learning..

该公司总部设在波士顿市中心，设计和制造创新产品，汇集质谱，微流体采样和分离，软件自动化和机器学习的力量。。

Forward Looking Statements

前瞻性声明

This press release includes “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the expected uses and capabilities of the Company’s products.

本新闻稿包括1995年“私人证券诉讼改革法”含义内的“前瞻性声明”。除历史事实陈述外的所有陈述均为前瞻性陈述，包括但不限于关于本公司产品的预期用途和能力的陈述。

Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under “Risk Factors” and elsewhere in the Company’s filings with the Securities and Exchange Commission which are available on the SEC's website at www.sec.gov.

诸如“可能”，“将会”，“期望”，“计划”，“预期”，“估计”，“意图”之类的词语和类似的表达（以及引用未来事件，条件或情况的其他词语或表达）旨在识别前瞻性陈述。这些前瞻性声明基于管理层当前的预期，涉及已知和未知的风险，不确定性和假设，这些风险，不确定性和假设可能导致实际结果与任何前瞻性声明表达或暗示的任何结果大不相同，包括“风险因素”中概述的风险以及公司与证券交易委员会提交的文件中的其他地方，这些文件可在SEC的网站www.SEC.gov上找到。

Additional information will be made available in the Company’s annual and quarterly reports and other filings that it makes from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results.

其他信息将在公司的年度和季度报告以及其与SEC不时提供的其他文件中提供。尽管公司认为其前瞻性报表中反映的预期是合理的，但不能保证未来的结果。

The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law..

本公司没有义务，也没有义务更新或修改本新闻稿中所作的任何前瞻性声明，以反映自本新闻稿发布之日起的变化，除非法律可能要求。。